Lipocine Inc. (LPCN)

2.88
0.05 1.80
NASDAQ : Health Technology
Prev Close 2.83
Open 2.79
Day Low/High 2.75 / 2.89
52 Wk Low/High 1.04 / 3.45
Volume 51.79K
Avg Volume 148.70K
Exchange NASDAQ
Shares Outstanding 24.84M
Market Cap 72.55M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Lipocine To Present At The Ladenburg Thalmann 2019 Healthcare Conference

Lipocine To Present At The Ladenburg Thalmann 2019 Healthcare Conference

SALT LAKE CITY, Sept. 17, 2019 /PRNewswire/ --  Lipocine Inc.

Lipocine To Participate In The Oppenheimer & Co. Fall Summit Focused On Specialty Pharma, Rare Disease & Gene Therapy

Lipocine To Participate In The Oppenheimer & Co. Fall Summit Focused On Specialty Pharma, Rare Disease & Gene Therapy

SALT LAKE CITY, Sept. 16, 2019 /PRNewswire/ --  Lipocine Inc.

Lipocine Announces Trial Date In Lipocine's Infringement Lawsuit Against Clarus Therapeutics And Will Seek A Permanent Injunction

Lipocine Announces Trial Date In Lipocine's Infringement Lawsuit Against Clarus Therapeutics And Will Seek A Permanent Injunction

SALT LAKE CITY, Aug. 27, 2019 /PRNewswire/ --  Lipocine Inc.

Lipocine Announces Second Quarter 2019 Financial And Operational Results

Lipocine Announces Second Quarter 2019 Financial And Operational Results

SALT LAKE CITY, Aug. 7, 2019 /PRNewswire/ -- Lipocine Inc.

Lipocine To Present At The Canaccord Genuity 39th Annual Growth Conference

Lipocine To Present At The Canaccord Genuity 39th Annual Growth Conference

SALT LAKE CITY, July 30, 2019 /PRNewswire/ --   Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that Dr.

Lipocine Receives FDA Clearance For Clinical Testing Its NASH Candidate, LPCN 1144, In Expanded Target Population

Lipocine Receives FDA Clearance For Clinical Testing Its NASH Candidate, LPCN 1144, In Expanded Target Population

SALT LAKE CITY, July 23, 2019 /PRNewswire/  --  Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has received clearance from the U.

Lipocine Set To Join Russell Microcap® Index

Lipocine Set To Join Russell Microcap® Index

SALT LAKE CITY, Utah, June 25, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it is set to join the Russell Microcap® Index at the conclusion...

Lipocine Announces TLANDO™ NDA PDUFA Action Date Of November 9, 2019

Lipocine Announces TLANDO™ NDA PDUFA Action Date Of November 9, 2019

SALT LAKE CITY, May 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.

Lipocine Announces First Quarter 2019 Financial And Operational Results

Lipocine Announces First Quarter 2019 Financial And Operational Results

SALT LAKE CITY, May 8, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2019, and provided a corporate update.

Lipocine Seeks Injunction Against The Marketing Of Clarus Therapeutics' JATENZO® For Testosterone Replacement Therapy

Lipocine Seeks Injunction Against The Marketing Of Clarus Therapeutics' JATENZO® For Testosterone Replacement Therapy

SALT LAKE CITY, April 3, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has filed suit against Clarus Therapeutics, Inc.

Lipocine Announces ABPM Labeling Study Results Consistent With Recently Approved Testosterone Replacement Therapy

Lipocine Announces ABPM Labeling Study Results Consistent With Recently Approved Testosterone Replacement Therapy

SALT LAKE CITY, March 27, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced findings from the Ambulatory Blood Pressure Monitoring clinical study...

Lipocine Late-Breaker Presentation At EASL Meeting To Detail LPCN 1144 MRI-PDFF Based Clinical Results On Reduction Of Liver Fat And Key Serum Biomarkers

Lipocine Late-Breaker Presentation At EASL Meeting To Detail LPCN 1144 MRI-PDFF Based Clinical Results On Reduction Of Liver Fat And Key Serum Biomarkers

SALT LAKE CITY, March 26, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today acceptance of their abstract for late-breaker presentation on LPCN 1144 clinical results as part of The International Liver...